Breaking Down TECON BIOLOGY Co.LTD Financial Health: Key Insights for Investors

TECON BIOLOGY Co.LTD (002100.SZ) posts mixed signals that demand a closer look: in the quarter ending September 30, 2025 revenue was 4.76 billion CNY (down 6.49% QoQ) while TTM revenue sits at 17.70 billion CNY (up 1.68% YoY) after a 2024 annual revenue of 17.18 billion CNY (‑9.72% YoY); profitability shows a 2024 net income of 605 million CNY with a net margin of 3.5% and EPS of 0.44 CNY (up 143.6% YoY), balance sheet metrics show total debt of 6.57 billion CNY against cash of 3.27 billion CNY for a net debt of 3.30 billion CNY and a debt/equity of 0.76, valuation sits at an enterprise value of 13.97 billion CNY with EV/EBITDA of 8.07 and a trailing P/E of 13.17, liquidity and cash flow include TTM operating cash flow of 1.16 billion CNY and 2024 free cash flow of 535.40 million CNY (‑28.7% YoY), and market expectations point to earnings growth of 18.8% p.a., revenue growth of 7.3% p.a., EPS rising ~19.1% p.a., and ROE reaching 10% in three years-read on to unpack what these figures mean for investors.

TECON BIOLOGY Co.LTD (002100.SZ) - Revenue Analysis

• Quarter (Q3 2025) revenue: 4.76 billion CNY (-6.49% QoQ)
• TTM revenue: 17.70 billion CNY (+1.68% YoY)
• FY 2024 revenue: 17.18 billion CNY (-9.72% YoY)
• Employees: 5,004; revenue per employee ≈ 3.54 million CNY
• Market cap: 9.42 billion CNY; P/S: 0.53

TECON BIOLOGY Co.LTD (002100.SZ) - Profitability Metrics

Key profitability figures for 2024 show TECON BIOLOGY Co.LTD generated a net income of 605 million CNY and delivered notable margin and return metrics that investors should weigh against growth dynamics and capital structure.

• Net income (2024): 605 million CNY
• Net profit margin: ~3.5%
• EPS (2024): 0.44 CNY (YoY increase: 143.6%)
• ROE: 8.6%
• Gross profit margin: 12.1%
• Operating profit margin: 3.67%
• Pretax profit margin: 3.56%

Investor-focused implications and actionable signals:

• The large EPS jump (143.6% YoY) warrants digging into drivers: operational improvement, lower costs, non-recurring gains, or share-count changes.
• Gross margin at 12.1% constrains pricing power; improvements in COGS or product mix are required to materially lift operating leverage.
• ROE of 8.6% is acceptable for a mid-cap industrial/biotech profile but suggests moderate capital efficiency versus peers.
• Operating and pretax margins clustered around ~3.6% indicate stable operating performance with limited non-operating volatility.
• Implied revenue (~17.29 billion CNY) provides scale context-compare against historical revenue and peer bands to judge growth sustainability.

For more investor context on share ownership, catalysts and market positioning, see: Exploring TECON BIOLOGY Co.LTD Investor Profile: Who's Buying and Why?

TECON BIOLOGY Co.LTD (002100.SZ) - Debt vs. Equity Structure

• Leverage profile: Debt-to-equity at 0.76 signals moderate leverage - not highly aggressive but notable debt exposure.
• Liquidity buffer: Cash of 3.27B CNY reduces net debt to 3.30B CNY, improving short- to medium-term flexibility.
• Interest servicing: Interest coverage of 5.05 implies comfortable ability to meet interest payments under current earnings.
• Short-term coverage: Current ratio 1.53 shows adequate coverage of current liabilities; quick ratio 0.63 highlights reliance on inventory for liquidity.
• Repayment horizon: Debt-to-EBITDA 3.79 places the company in a moderate leverage bucket - manageable but sensitive to EBITDA declines.

TECON BIOLOGY Co.LTD (002100.SZ) - Liquidity and Solvency

Key liquidity and solvency metrics for TECON BIOLOGY Co.LTD highlight solid operating cash generation alongside meaningful leverage. The figures below reflect the company's most recent reported results and trailing twelve-month activity.

• Operating cash flow (TTM): ¥1.16 billion CNY
• Capital expenditures (2024): ¥626 million CNY
• Free cash flow (2024): ¥535.40 million CNY (down 28.7% YoY)
• Cash & cash equivalents: ¥3.27 billion CNY
• Net cash position: -¥3.29 billion CNY (debt exceeds cash)

• Liquidity cushion: ¥3.27B in cash provides near-term flexibility for working capital and debt servicing.
• Leverage context: implied total debt of ~¥6.56B against stable operating cash flows suggests leverage is serviceable but merits monitoring.
• Cash generation vs. investment: positive free cash flow despite elevated capex demonstrates ongoing capacity to fund growth while maintaining liquidity.

For additional corporate context, see Mission Statement, Vision, & Core Values (2026) of TECON BIOLOGY Co.LTD.

TECON BIOLOGY Co.LTD (002100.SZ) - Valuation Analysis

• Market capitalization: 9.15 billion CNY
• Enterprise value (EV): 13.97 billion CNY
• Trailing P/E: 13.17
• Forward P/E: 14.18
• Price-to-book (P/B): 1.06
• Price-to-sales (P/S): 0.52
• EV/EBITDA: 8.07
• EV/FCF: 12.45

Key implications of these metrics:

• A P/B near 1.06 implies the market values equity close to its book value, suggesting limited intangible premium priced in.
• Trailing and forward P/E in the low-to-mid teens signal moderate earnings valuation - not expensive for growth-light sectors but not deeply discounted either.
• EV/EBITDA of 8.07 is attractive versus many healthcare peers, indicating reasonable enterprise-level valuation relative to operating profitability.
• EV/FCF at 12.45 reflects a fair multiple on cash generation; investors should compare to historical FCF conversion and sector norms.

For additional context on corporate background, ownership and how value is created, see: TECON BIOLOGY Co.LTD: History, Ownership, Mission, How It Works & Makes Money

TECON BIOLOGY Co.LTD (002100.SZ) - Risk Factors

• Competitive position and scale disadvantage: TECON's revenue scale is materially smaller than national leaders, constraining procurement leverage and distribution breadth.
• Geographic & logistical friction: A Xinjiang production base gives advantaged raw material access but increases transit time and freight costs to eastern coastal markets versus coastal rivals.
• Capital intensity from vertical integration: The company's strategy of owning upstream processing and some downstream channels raises recurring capital expenditure requirements and fixed-cost absorption risk.
• Margin compression and operational efficiency: A reported net margin of ~3.5% indicates limited buffer against cost inflation or pricing pressure.
• Credit exposure from financial services: Financing products tied to agricultural counterparties create additional revenue but concentrate credit risk in a cyclical sector.

• Procurement and distribution risk: Smaller purchase volumes reduce bargaining power on input prices (fertilizer, seed, feed ingredients) and increase per-unit logistics cost.
• Inventory and working capital cycles: Agricultural seasonality can induce large swings in inventories and receivables; short-term cash strain can magnify if margins compress.
• Capital allocation trade-offs: Continued high CapEx to support vertical integration may crowd out dividends, share buybacks or deleveraging.
• Credit/finance portfolio concentration: Default rates in agricultural lending can spike with droughts, disease outbreaks or commodity price collapses-adversely affecting financing revenue and provisioning needs.
• Regulatory and trade risk: Local and national policy shifts (subsidies, environmental standards, export controls) can alter cost structure and market access.

• 2-3 percentage point fall in gross margin combined with stagnant sales - impacts EBITDA and cash flow given current leverage and CapEx run-rate.
• Increase in financing portfolio NPLs from 1% to 5% - requires elevated provisioning, pressuring net income and equity.
• Logistics disruption or tariff increase raising eastbound transport costs by 15-25% - compresses margins and may force price increases that dampen demand.

TECON BIOLOGY Co.LTD (002100.SZ) - Growth Opportunities

• Revenue CAGR: 7.3% per annum (near-term consensus).
• Earnings (net income) CAGR: 18.8% per annum.
• EPS CAGR: 19.1% per annum.
• Return on equity target: ~10% within three years.

• Diversified portfolio across feed, edible oils, and veterinary biological products - multiple, partially uncorrelated revenue streams within China's essential food and agricultural supply chain.
• Vertically integrated model: feed production → oil processing → veterinary products, enabling capture of upstream and downstream margins and inventory/quality control advantages.
• Strategic mix shift toward higher-margin activities (veterinary biologicals, value-added feed additives) and complementary services (financial solutions for farmers), which mitigates pure-commodity exposure and smooths earnings volatility.

• Feed segment: volume growth tied to domestic livestock recovery and stable pricing; margin expansion via formulation upgrades and specialty additives.
• Oil processing: throughput optimization and by‑product valorization can lift gross margins.
• Veterinary biologicals: R&D-led product mix (vaccines, biologics) offers premium pricing and recurring revenues with higher gross margins than commodity feed.
• Financial services to agricultural clients: fee and interest income plus cross-sell of inputs increases customer stickiness and reduces working-capital cyclicality.